| Cash Flow | 2025-09-30 |
|---|---|
| Net loss | -46,377 |
| Share based compensation | 11,549 |
| Incentive and tax receivables | -1,640 |
| Prepaid expenses and deposits | -502 |
| Accounts payable | -5,378 |
| Accrued liabilities | -943 |
| Deferred grant income | 37 |
| Net cash used in operating activities | -39,044 |
| Issuance of common shares, net of share issue costs | 9,198 |
| Payment for taxes related to cashless exercise of options | 2,707 |
| Proceeds from exercise of stock options | 2,943 |
| Net cash provided by financing activities | 9,434 |
| (decrease) increase in cash and cash equivalents during the year | -29,610 |
| Cash and cash equivalents at beginning of period | 132,187 |
| Cash and cash equivalents at end of period | 102,577 |
ANAVEX LIFE SCIENCES CORP. (AVXL)
ANAVEX LIFE SCIENCES CORP. (AVXL)